Associated Papers
The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L).
Pan Y et al.
Anti-cancer Drugs, 2025
Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.
Yuejian et al.
Investigational New Drugs, 2025
Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review.
Wang S et al.
Frontiers in Medicine, 2025
An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.
Boukansa S et al.
Journal of Medical Case Reports, 2024
[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].
Miao Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2023
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.
Luo Z et al.
Anti-cancer Drugs, 2023
EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report.
Pan H et al.
Frontiers in Oncology, 2023
Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review.
Li L et al.
Frontiers in Pharmacology, 2023
Prognostic and predictive role of liquid biopsy in lung cancer patients.
Goksel T et al.
Frontiers in Oncology, 2023
A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review.
Yang X et al.
Heliyon, 2022
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.
Longo V et al.
Thoracic Cancer, 2021
Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
Long X et al.
Oncotargets and Therapy, 2020
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
Masood A et al.
Seminars in Oncology, 2019
The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.
Qin BD et al.
Oncotargets and Therapy, 2018
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report.
Al-Nusair J et al.
Journal of Investigative Medicine High Impact Case Reports, 0
Select a paper to view details